Diagnosis and Treatment of Atypical Hemolytic Uremic Syndrome

Catherine Broome, MD Associate Clinical Professor of Medicine Lombardi Cancer Center Georgetown University Hospital Washington, DC H&O What is atypical hemolytic uremic syndrome? CB Atypical hemolytic uremic syndrome […]

Advances in the Treatment of Neuroblastoma

Susan Cohn, MD Professor of Pediatrics Director, Clinical Research Section of Pediatric Hematology/Oncology Comer Children’s Hospital The University of Chicago Chicago, Illinois H&O What is the treatment […]

Cancer Vaccines

Yusuke Nakamura, MD, PhD Professor, Laboratory of Molecular Medicine Institute of Medical Science The University of Tokyo Tokyo, Japan H&O What are some recent developments in tumor […]

Advances in Biomarkers for Targeted Agents

Advances in Biomarkers for Targeted Agents Michael L. Maitland, MD, PhD Assistant Professor of Medicine Section of Hematology/Oncology Associate Director, Committee on Clinical Pharmacology and Pharmacogenomics […]

Next Generation Clinical Trials

Donald A. Berry, PhD Professor, Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston, Texas H&O What is the current method that is used […]

Nilotinib Risk Evaluation and Mitigation Strategy

Maria Baer, MD Professor of Medicine University of Maryland School of Medicine Director, Hematologic Malignancies University of Maryland Greenebaum Cancer Center Baltimore, Maryland H&O Why does the […]

Off-Label Drug Utilization in Oncology

Jonas A. de Souza, MD Instructor of Medicine Section of Hematology/Oncology University of Chicago Medical Center Chicago, Illinois H&O What is the definition of off-label drug utilization? […]

Rationing Cancer Care: the Emerging Debate

Daniel Callahan, PhD Senior Research Scholar President Emeritus The Hastings Center Garrison, New York H&O Can you provide some background on the current state of cancer care […]

Current Dilemmas in Carboplatin Dosing

Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine Director, Center for Personalized Therapeutics Associate Director for Clinical Sciences Cancer Research Center The University of […]

Predictive and Prognostic Markers in Cancer

Daniel Hayes, MD Clinical Director, Breast Oncology Program Stuart B. Padnos Professor in Breast Cancer Research University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan H&O Can […]

New Strategies to Prevent and Manage Bone Complications in Cancer

Allan Lipton, MD Professor of Medicine/Oncology Penn State University Milton S. Hershey College of Medicine Hershey, Pennsylvania H&O What factors are involved in the risk of bone […]

Importance of Circulating Tumor Cells in Diagnosis, Prognosis, and Treatment Selection

Mara Aspinall, MBA,1 and Gary Palmer, MD, JD, MBA, MPH2 1Chief Executive Officer 2Chief Medical Officer On-Q-ity Waltham, Massachusetts H&O What are circulating tumor cells? MA/GP Circulating tumor cells […]

Abiraterone in Prostate Cancer

Charles Ryan, MD Associate Clinical Professor Department of Medicine UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California H&O What is abiraterone? What is its mechanism […]

HPV and Its Effect on Head and Neck Cancer Prognosis

Maura Gillison, MD, PhD Jeg Coughlin Chair of Cancer Research Professor of Internal Medicine & Epidemiology Ohio State University Medical Center Columbus, Ohio H&O Can you provide […]

Cost-Effectiveness Analysis in Oncology

David Meltzer, MD Associate Professor, Department of Medicine Associated Faculty Member, Harris School and the Department of Economics University of Chicago Chicago, Illinois H&O How has cost-effectiveness analysis […]

Update on CYP2D6 and Its Impact on Tamoxifen Therapy

Matthew P. Goetz, MD Associate Professor of Oncology and Pharmacology Mayo Clinic Rochester, Minnesota H&O What is CYP2D6? What is its significance in regard to tamoxifen and […]

Companion Diagnostics

Robert Becker, Jr, MD, PhD1, and Elizabeth Mansfield, PhD2 1Chief Medical Officer 2Director of the Personalized Medicine Staff OIVD/CDRH/FDA Silver Spring, Maryland H&O What is a companion diagnostic? […]

The National Cancer Institute Experimental Therapeutics Program

James H. Doroshow, MD Director Division of Cancer Treatment and Diagnosis National Cancer Institute Bethesda, Maryland H&O What is the NExT Program? JD The NExT (NCI Experimental Therapeutics) […]

Cost of New Oncology Drugs

Lee Newcomer, MD Senior Vice President, Oncology United Healthcare Edina, Minnesota H&O Why is the cost debate most prominent in oncology as opposed to other diseases? LN There […]

New Treatments for Sarcoma

New Treatments for Sarcoma Ian Judson, MA, MB, BChir, MD, FRCP Professor of Cancer Pharmacology , The Royal Marsden Hospital/Institute of Cancer Research Sycamore House, Sutton, Surrey UK H&O […]